Literature DB >> 17368771

The decay accelerating factor mutation I197V found in hemolytic uraemic syndrome does not impair complement regulation.

D Kavanagh1, R Burgess, D Spitzer, A Richards, M L Diaz-Torres, J A Goodship, D E Hourcade, J P Atkinson, T H J Goodship.   

Abstract

Hemolytic uremic syndrome is the clinical triad of thrombocytopenia, microangiopathic hemolytic anaemia and acute renal failure. Cases not associated with a preceding Shiga-like toxin producing Escherichia coli are described as atypical HUS (aHUS). Approximately 50% of patients with aHUS have mutations in one of three complement regulatory proteins, Factor H (CFH), membrane cofactor protein (MCP;CD46) or factor I (IF). A common feature of these three proteins is that they regulate complement by cofactor activity. Decay accelerating factor (DAF; CD55) regulates the complement system by disassociating the alternative and classical pathway convertases. Like CFH and MCP, the gene for DAF lies within the regulators of complement activation (RCA) gene cluster at 1q32. In 1998, we described linkage to this region in families with aHUS which led to the discovery of mutations in CFH and MCP. We therefore genotyped DAF in a panel of 46 aHUS patients including families with linkage to the RCA cluster. A mutation, I197V, was identified in one patient with familial HUS which was not found in 100 healthy controls. Molecular modelling of this mutation shows that the I197V mutation does not reside in an area which would be predicted to be important in decay accelerating activity. The expression of I197V on EBV-transformed B lymphocytes was equivalent to that of wild type controls. There was no significant decrease in decay acceleration activity of the recombinantly produced I197V mutant compared with wild type, as measured by a complement-mediated lytic assay. In conclusion, this study, identifies only one mutation in DAF in 46 patients with aHUS. This mutation, I197V, does not impair complement regulation and cannot be implicated in the pathogenesis of aHUS in this patient. This suggests that the complement regulatory abnormality in aHUS is principally one of deficient cofactor activity rather than of decay acceleration activity.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17368771     DOI: 10.1016/j.molimm.2007.01.036

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  9 in total

1.  Autoantibodies to CD59, CD55, CD46 or CD35 are not associated with atypical haemolytic uraemic syndrome (aHUS).

Authors:  Rachael Watson; Emma Wearmouth; Amy-Claire McLoughlin; Arthur Jackson; Sophie Ward; Paula Bertram; Karim Bennaceur; Catriona E Barker; Isabel Y Pappworth; David Kavanagh; Susan M Lea; John P Atkinson; Timothy H J Goodship; Kevin J Marchbank
Journal:  Mol Immunol       Date:  2014-08-21       Impact factor: 4.407

Review 2.  Review: Complement and its regulatory proteins in kidney diseases.

Authors:  Allison M Lesher; Wen-Chao Song
Journal:  Nephrology (Carlton)       Date:  2010-10       Impact factor: 2.506

3.  Allelic variants of complement genes associated with dense deposit disease.

Authors:  Maria Asuncion Abrera-Abeleda; Carla Nishimura; Kathy Frees; Michael Jones; Tara Maga; Louis M Katz; Yuzhou Zhang; Richard J H Smith
Journal:  J Am Soc Nephrol       Date:  2011-07-22       Impact factor: 10.121

4.  Factor I autoantibodies in patients with atypical hemolytic uremic syndrome: disease-associated or an epiphenomenon?

Authors:  David Kavanagh; Isabel Y Pappworth; Holly Anderson; Christine M Hayes; Iain Moore; Eva-Maria Hunze; Karim Bennaceur; Pietro Roversi; Susan Lea; Lisa Strain; Roy Ward; Nick Plant; Corina Nailescu; Timothy H J Goodship; Kevin J Marchbank
Journal:  Clin J Am Soc Nephrol       Date:  2012-01-05       Impact factor: 8.237

Review 5.  Genetics and complement in atypical HUS.

Authors:  David Kavanagh; Tim Goodship
Journal:  Pediatr Nephrol       Date:  2010-06-06       Impact factor: 3.714

Review 6.  Complement Dysregulation and Disease: Insights from Contemporary Genetics.

Authors:  M Kathryn Liszewski; Anuja Java; Elizabeth C Schramm; John P Atkinson
Journal:  Annu Rev Pathol       Date:  2016-12-05       Impact factor: 23.472

7.  Production of biologically active complement factor H in therapeutically useful quantities.

Authors:  Christoph Q Schmidt; Fern C Slingsby; Anna Richards; Paul N Barlow
Journal:  Protein Expr Purif       Date:  2010-12-10       Impact factor: 1.650

8.  Complement factor B mutations in atypical hemolytic uremic syndrome-disease-relevant or benign?

Authors:  Maria Chiara Marinozzi; Laura Vergoz; Tania Rybkine; Stephanie Ngo; Serena Bettoni; Anastas Pashov; Mathieu Cayla; Fanny Tabarin; Mathieu Jablonski; Christophe Hue; Richard J Smith; Marina Noris; Lise Halbwachs-Mecarelli; Roberta Donadelli; Veronique Fremeaux-Bacchi; Lubka T Roumenina
Journal:  J Am Soc Nephrol       Date:  2014-03-20       Impact factor: 10.121

9.  Increased expression of complement regulators CD55 and CD59 on peripheral blood cells in patients with EAHEC O104:H4 infection.

Authors:  Werner Dammermann; Pim Schipper; Sebastian Ullrich; Katharina Fraedrich; Julian Schulze Zur Wiesch; Thorben Fründt; Gisa Tiegs; Ansgar Lohse; Stefan Lüth
Journal:  PLoS One       Date:  2013-09-23       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.